The weight-loss drug cetilistat improves weight and glycemic control to the same degree as orlistat among obese metformin-treated individuals with Type 2 diabetes, but is better tolerated by patients, report researchers.

Both orlistat and cetilistat are gastrointestinal and pancreatic lipase inhibitors, which act to prevent fat absorption by stopping the breakdown of triglycerides in the intestine.

onlinepharmacylist.net/17/1/Xenical/”>Orlistat is effective for promoting weight loss, but has been reported to cause unpleasant gastrointestinal side effects such as oily, loose stools, fecal incontinence, frequent bowel movements, and flatulence.

In this study, Andrew Bryson (Alizyme Therapeutics Ltd, Cambridge, UK) and colleagues compared the efficacy and tolerability of cetilistat and orlistat in a 12-week randomized controlled study including 517 patients, aged 53.4 years on average, with Type 2 diabetes being treated with metformin. All participants had a body mass index between 28 and 45 kg/m².

The researchers randomly assigned participants to receive treatment with placebo (n=104), orlistat 120 mg three times daily (n=101), or cetilistat 40 mg (n=102), 80 mg (n=104), or 120 mg (n=106) three times daily.

Writing in the journal Obesity, the researchers report that individuals in the orlistat 120-mg and cetilistat 80- and 120-mg groups lost a significant amount of weight compared with placebo at 3.78, 3.85, and 4.32 kg, respectively, versus 2.86 kg.

Patients in these groups also had significant improvements in glycated hemoglobin (HbA1c) with corresponding reductions of 0.53%, 0.51%, and 0.54% versus 0.37%.

Of note, cetilistat 40 mg did not produce significant improvements in weight or HbA1c compared with placebo.

Although more patients taking cetilistat reported side effects (86.7??”89.2%) than did patients taking placebo (72.8%), the side effects with cetilistat were milder and less frequent than among orlistat-treated patients (92.6%).

Indeed, the frequency of study discontinuation due to adverse events was only 0.8??”2.5% for cetilistat-treated individuals compared with 4.0% and 11.6% for placebo- and orlistat-treated individuals, respectively. Most adverse events were gastrointestinal as previously reported.

“The high level of tolerability of cetilistat in this patient group, with the consequent increase in compliance, could be clinically significant in the management of this patient population,” conclude Bryson et al.

MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009

Free abstract

MedWire Links
Orlistat_improves_glycemic_control_in_patients_with_Type_2_diabetes.html” class=”date”>Orlistat improves glycemic control in patients with Type 2 diabetes
Meta-analysis clarifies anti-obesity therapy benefits
Orlistat_helps_maintain_post-dieting_weight_loss.html” class=”date”>Orlistat helps maintain post-dieting weight loss

Japanese researchers report a high prevalence of metabolic syndrome components in addition to hyperglycemia in children at the time of Type 2 diabetes diagnosis.

The presence of metabolic syndrome components is frequently reported in adults with Type 2 diabetes placing them at increased risk for cardiovascular disease.

To determine whether a similar situation exists in children, Tatsuhiko Urakami (Nihon University School of Medicine, Tokyo, Japan) and co-workers examined the prevalence of components other than hyperglycemia at the time of Type 2 diabetes diagnosis in Japanese schoolchildren.

Data from 112 children diagnosed following a school screening program were examined. Measurements obtained at diagnosis included body weight, blood pressure, fasting serum triglycerides, and high-density lipoprotein HDL) cholesterol.

The researchers used the new International Diabetes Federation criteria for the metabolic syndrome in children aged between 10 and 16 years, which requires the presence of abdominal obesity plus two or more of the other components (elevated triglycerides, reduced HDL cholesterol, hypertension, and hyperglycemia).

As waist circumference was not routinely measured at the school screening, obesity was defined as those who were at least 20.0% overweight, compared with age- and height-matched ideal weight controls.

“We found that a total of 35.8% of children with Type 2 diabetes had more than two of the other components of the metabolic syndrome in addition to hyperglycemia,” report the authors in the journal Pediatric Diabetes.

Of the 112 children, 15.2% had no other components of the metabolic syndrome besides hyperglycemia, 49.1% had only one other component, 17.0% had two other components, and 18.8% had three or more components in addition to hyperglycemia.

Of the other components, the prevalence of obesity was 83.0%, of increased triglycerides 33.0%, decreased HDL cholesterol 21.4%, and elevated blood pressure 11.6%.

Of the non-obese children, 89.5% had no other components of the metabolic syndrome except for hyperglycemia.

“Early detection of other components of the metabolic syndrome would appear to be of importance for preventing the development of cardiovascular disease in children with Type 2 diabetes,” conclude the authors.

MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009

Free abstract

This article will give information on the healing effect of resveratrol on type II diabetes. How can this supplement help you with this problem? Type II diabetes according to experts tends to be a nutrition disease, which is the result of metabolism disorder due to food intake. It can lead to a high level of sugar in the body or obesity.

Are you positive that a pill can help in relieving and wiping away the effects of cancer, aging, and diabetes? It might sound impossible that a natural compound can treat the said health problems but it is very possible with resveratrol. There are various experiments done specifically by Dr. David Sinclair of the Harvard Medical School branding resveratrol as the ‘fountain of life’.

What is the healing effect of resveratrol on type II diabetes? It is a total positive breakthrough in the medical and scientific field for it can stop not only cancer and rapid ageing processes, but also high blood sugar levels. Resveratrol can prevent the secretion of amylin, which is responsible for the buildup of hard shell fibrils that can kill healthy cells. This natural compound has the capacity to block and stop its formations.

Indeed, resveratrol can provide a helpful and positive effect. It has seventy ingredients that make it very powerful. Examples of these are:

1. Turmeric

2. Decaffeinated Green Tea

It promotes long life, good physical appearance, high self-esteem, a healthy internal body, and a happier and healthier totality of the person. Keep in mind that one must seek the advice and approval of a physician to make sure that it is applicable for you. Indeed, prevention is always the best cure. Life is super short for us to feel the pain and sufferings caused by lifestyle and eating habits.